Vertex Pharmaceuticals Incorporated Earnings

Vertex Pharmaceuticals Incorporated’s revenue jumped 12.06% since last year same period to $2964.7Mn in the Q2 2025. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated 7.02% jump in its revenue since last 3-months.

Vertex Pharmaceuticals Incorporated’s net profit jumped 128.74% since last year same period to $1032.9Mn in the Q2 2025. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated 59.82% jump in its net profits since last 3-months.

Vertex Pharmaceuticals Incorporated’s net profit margin jumped 125.65% since last year same period to 34.84% in the Q2 2025. On a quarterly growth basis, Vertex Pharmaceuticals Incorporated has generated 49.33% jump in its net profit margins since last 3-months.

Vertex Pharmaceuticals Incorporated’s price-to-earnings ratio after this Q2 2025 earnings stands at 27.73.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current quarter stand at 4.63 - a 8.18% jump from last quarter’s estimates.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) estimates for the current year stand at 4.63.

Vertex Pharmaceuticals Incorporated’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Vertex Pharmaceuticals Incorporated has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.